WO2002007713A2 - Medicament contenant du cilansetron pour traiter des patients masculins atteints du syndrome du colon irritable mais ne souffrant pas de constipation opiniatre - Google Patents

Medicament contenant du cilansetron pour traiter des patients masculins atteints du syndrome du colon irritable mais ne souffrant pas de constipation opiniatre Download PDF

Info

Publication number
WO2002007713A2
WO2002007713A2 PCT/EP2001/008260 EP0108260W WO0207713A2 WO 2002007713 A2 WO2002007713 A2 WO 2002007713A2 EP 0108260 W EP0108260 W EP 0108260W WO 0207713 A2 WO0207713 A2 WO 0207713A2
Authority
WO
WIPO (PCT)
Prior art keywords
cilansetron
patients
ibs
use according
treatment
Prior art date
Application number
PCT/EP2001/008260
Other languages
German (de)
English (en)
Other versions
WO2002007713A3 (fr
Inventor
Werner Cautreels
Claus Rudolf Steinborn
Heinz Günter KRAUSE
Steven David Caras
Egbertus Hendrikus Evert Biesheuvel
Albertus Hermannus Dirk Plekkenpol
Original Assignee
Solvay Pharmaceuticals Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10123447A external-priority patent/DE10123447A1/de
Priority to JP2002513449A priority Critical patent/JP2004504343A/ja
Priority to BR0112690-3A priority patent/BR0112690A/pt
Priority to MXPA02012917A priority patent/MXPA02012917A/es
Priority to IL15397201A priority patent/IL153972A0/xx
Priority to SK127-2003A priority patent/SK1272003A3/sk
Application filed by Solvay Pharmaceuticals Gmbh filed Critical Solvay Pharmaceuticals Gmbh
Priority to CA002417677A priority patent/CA2417677A1/fr
Priority to KR10-2003-7000038A priority patent/KR20030019951A/ko
Priority to HU0301479A priority patent/HUP0301479A2/hu
Priority to AU2001276409A priority patent/AU2001276409A1/en
Priority to EP01954044A priority patent/EP1307195A2/fr
Publication of WO2002007713A2 publication Critical patent/WO2002007713A2/fr
Publication of WO2002007713A3 publication Critical patent/WO2002007713A3/fr
Priority to NO20030373A priority patent/NO20030373D0/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • the present invention relates to a new medical use of cilansetron or its acid addition salts.
  • Cilansetron is a 5HT 3 receptor antagonist, which falls under the scope of the European patent EP 0 297 651 Bl and which has the chemical name (R) - (-) -4, 5, 6, 8, 9, 10- hexahydro- 10- [(2-methyl-lH-imidazol-l-yl) methyl] -llH-pyrido- [3, 2, 1-j] -carbazol-11-one carries.
  • European patent EP 0 601 345 B1 already discloses the use of, inter alia, cilansetron for the production of pharmaceutical preparations for the treatment of functional disorders of the lower intestinal tract associated with increased sensitivity to pain and / or abnormally accelerated stool passage in the colon area in larger mammals and humans.
  • non-constipative diarrhea-predominant IBS patient group
  • WO 99/17755 mentions alosetron, which in clinical trials showed significantly better efficacy in female IBS patients compared to efficacy in male IBS patients. In these clinical trials, male test subjects treated with alosetron did not find any significant improvement in their condition compared to the placebo group.
  • cilansetron is stated to be within the scope of the disclosure.
  • IBS irritable bowel syndrome
  • IBS refers to a group of symptoms associated with pain and / or a feeling of discomfort in the lower abdomen and changed bowel activities such as diarrhea, constipation (constipation) or alternating diarrhea and constipation. Since no clearly definable physiological or other organic findings can be cited as the cause of IBS, the medical diagnosis of this disease is usually based on the absence or presence of a number of symptoms which are generally regarded as typical for IBS and, for example, in the " Ro e Criteria "(cf. WG Thompson et al., Gastroent. Int. 2 (1989) 92-95; WG Thompson et al., Gut 45/11 (1999) II 43 - II 47; WG Thompson, Lancet 341 ( 1993) 1569 - 1572).
  • cilansetron can preferably be used in the form of the cilansetron hydrochloride.
  • the cilansetron hydrochloride monohydrate is usually used.
  • Further pharmacologically acceptable acid addition salts of cilansetron are known from EP 0 297 651 B1.
  • BID dosage a dosage of 5HT 3 receptor antagonists
  • TID dosage a dosage of IBS patients of both sexes.
  • Examples of 5HT 3 receptor antagonists which can be administered more advantageously in triple daily doses include alosetron, azasetron, dolasetron, granisetron, indisetron, itasetron, lerisetron, ondansetron, ramosetron, tropisetron and (R) -zacoprid. It has proven to be particularly advantageous for the treatment of IBS patients of both sexes to administer cilansetron or its pharmacologically acceptable acid addition salts and / or solvates to the patients three times a day, for example in doses between 1 mg and 16 mg per administration.
  • cilansetron or a pharmacologically acceptable acid addition salt of cilansetron can be contained according to the invention in solid or liquid pharmaceutical preparations together with customary pharmaceutical auxiliaries and / or carriers.
  • solid preparations are orally administrable preparations such as tablets, dragees, capsules, powders or granules or suppositories.
  • These preparations can pharmaceutically customary inorganic and / or organic carriers, such as. B. talc, milk sugar or starch in addition to pharmaceutically customary auxiliaries, for example lubricants or tablet disintegrants.
  • Liquid preparations such as suspensions or emulsions of cilansetron can contain the usual diluents such as water, oils and / or suspending agents such as polyethylene glycols and the like. Additional auxiliaries can also be added, e.g. B. preservatives, flavor corrections and the like.
  • Cilansetron or a pharmacologically acceptable acid addition salt of cilansetron can be mixed and formulated with the pharmaceutical auxiliaries and / or carriers in a manner known per se.
  • cilansetron or an acid addition salt can be mixed, for example, with the auxiliaries and / or excipients in a conventional manner and granulated wet or dry. The granules or powder can be filled directly into capsules or pressed into tablet cores in the usual way. If desired, these can be dragged in a known manner.
  • the active ingredient is mixed with cornstarch and fine powdered lactose in a mixer.
  • the resulting mixture is moistened with a 20% solution of polyvinylpyrolidone (Kollidon 25 R from BASF) in demineralized water. If necessary, further demineralized water is added.
  • the moist granulate is passed through a 2 mm sieve. , dried on trays at 40 ° C and then passed through a 1 mm sieve (Frewitt machine). After mixing the granules with magnesium stearate and talc, tablets with a weight of 114 mg are pressed therefrom, so that each tablet contains 4 mg of active ingredient.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne l'utilisation de cilansétron pour traiter des patients masculins atteints du syndrome du colon irritable mais ne souffrant pas de constipation opiniâtre.
PCT/EP2001/008260 2000-07-26 2001-07-18 Medicament contenant du cilansetron pour traiter des patients masculins atteints du syndrome du colon irritable mais ne souffrant pas de constipation opiniatre WO2002007713A2 (fr)

Priority Applications (11)

Application Number Priority Date Filing Date Title
EP01954044A EP1307195A2 (fr) 2000-07-26 2001-07-18 Medicament contenant du cilansetron pour traiter des patients masculins atteints du syndrome du colon irritable mais ne souffrant pas de constipation opiniatre
KR10-2003-7000038A KR20030019951A (ko) 2000-07-26 2001-07-18 변비가 없는 남성 과민성대장증후군 환자의 치료를 위한실란세트론 함유 의약
MXPA02012917A MXPA02012917A (es) 2000-07-26 2001-07-18 Medicamentos que contienen cilansetron para el tratamiento de pacientes de ibs masculinos no estre°idos.
IL15397201A IL153972A0 (en) 2000-07-26 2001-07-18 Medicaments containing cilansetron for treating non-obstipated male ibs patients
SK127-2003A SK1272003A3 (en) 2000-07-26 2001-07-18 Medicaments containing cilansetron for treating non-obstipated male IBS patients
JP2002513449A JP2004504343A (ja) 2000-07-26 2001-07-18 非便秘性の男性ｉｂｓ患者の治療のためのシランセトロン含有医薬品
CA002417677A CA2417677A1 (fr) 2000-07-26 2001-07-18 Medicament contenant du cilansetron pour traiter des patients masculins atteints du syndrome du colon irritable mais ne souffrant pas de constipation opiniatre
BR0112690-3A BR0112690A (pt) 2000-07-26 2001-07-18 Medicamento contendo cilansetron para o tratamento de pacientes ibs masculinos não-obstipativos
HU0301479A HUP0301479A2 (hu) 2000-07-26 2001-07-18 Cilansetron alkalmazása nemobstipációs férfi IBS-betegek kezelésére szolgáló gyógyszerkészítmény elżállítására
AU2001276409A AU2001276409A1 (en) 2000-07-26 2001-07-18 Medicaments containing cilansetron for treating non-obstipated male ibs patients
NO20030373A NO20030373D0 (no) 2000-07-26 2003-01-24 Medikamenter inneholdende cilansetron for behandling av ikke- obstiperte IBS-pasienter av hannkjönn

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE10036645 2000-07-26
DE10036645.7 2000-07-26
DE10123447.3 2001-05-14
DE10123447A DE10123447A1 (de) 2000-07-26 2001-05-14 Cilansetron enthaltende Arzneimittel zur Behandlung nicht-obstipativer männlicher IBS-Patienten

Publications (2)

Publication Number Publication Date
WO2002007713A2 true WO2002007713A2 (fr) 2002-01-31
WO2002007713A3 WO2002007713A3 (fr) 2002-11-14

Family

ID=26006529

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2001/008260 WO2002007713A2 (fr) 2000-07-26 2001-07-18 Medicament contenant du cilansetron pour traiter des patients masculins atteints du syndrome du colon irritable mais ne souffrant pas de constipation opiniatre

Country Status (16)

Country Link
EP (1) EP1307195A2 (fr)
JP (1) JP2004504343A (fr)
CN (1) CN1444479A (fr)
AR (1) AR028970A1 (fr)
AU (1) AU2001276409A1 (fr)
BR (1) BR0112690A (fr)
CA (1) CA2417677A1 (fr)
CZ (1) CZ2003158A3 (fr)
HU (1) HUP0301479A2 (fr)
IL (1) IL153972A0 (fr)
MX (1) MXPA02012917A (fr)
NO (1) NO20030373D0 (fr)
PL (1) PL363517A1 (fr)
RU (1) RU2003104798A (fr)
SK (1) SK1272003A3 (fr)
WO (1) WO2002007713A2 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005072730A1 (fr) * 2004-01-30 2005-08-11 Astellas Pharma Inc. Agent therapeutique pour le syndrome de l’intestin irritable de type diarrhoe
WO2005073220A1 (fr) * 2004-01-30 2005-08-11 Yamanouchi Pharmaceutical Co., Ltd. Remede contre le syndrome du colon irritable avec diarrhee
JP2006008707A (ja) * 2005-09-21 2006-01-12 Astellas Pharma Inc 下痢型過敏性腸症候群治療剤
US7470690B2 (en) 2002-07-10 2008-12-30 Dynogen Pharmaceuticals, Inc. 4-(2-Fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D)pyrimidine in the treatment of functional bowel disorder

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7662831B2 (en) 2006-07-27 2010-02-16 Wyeth Llc Tetracyclic indoles as potassium channel modulators
US7601856B2 (en) 2006-07-27 2009-10-13 Wyeth Benzofurans as potassium ion channel modulators

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999017755A2 (fr) * 1997-10-07 1999-04-15 Glaxo Group Limited Medicaments
WO2001045685A2 (fr) * 1999-12-20 2001-06-28 Glaxo Group Limited Formulations d'agonistes adenosine a1

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999017755A2 (fr) * 1997-10-07 1999-04-15 Glaxo Group Limited Medicaments
WO2001045685A2 (fr) * 1999-12-20 2001-06-28 Glaxo Group Limited Formulations d'agonistes adenosine a1

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
"Irritable bowel syndrome - Cilansetron." MANUFACTURING CHEMIST, (2000) 71/2 (22)., XP001042043 *
BEGLINGER, C. (1) ET AL: "Effect of cilansetron, a specific 5-HT-3 receptor antagonist, on gastrointestinal motor function in normal subjects." NAUNYN-SCHMIEDEBERG'S ARCHIVES OF PHARMACOLOGY, (1996) VOL. 353, NO. 4 SUPPL., PP. R163. MEETING INFO.: 37TH SPRING MEETING OF THE GERMAN SOCIETY FOR EXPERIMENTAL AND CLINICAL PHARMACOLOGY AND TOXICOLOGY MAINZ, GERMANY MARCH 12-14, 1996, XP001058426 *
BOTELLA, A. ET AL: "Intracolonic glycerol induces abdominal contractions in rats: role of 5-HT3 receptors" FUNDAM. CLIN. PHARMACOL. (1998), 12(6), 619-623, XP001058254 *
RABASSEDA, X. ET AL: "Cilansetron" DRUGS FUTURE (1999), 24(5), 475-482, XP001058216 *
STACHER, GEORG ET AL: "Effects of the 5-HT3 antagonist cilansetron vs placebo on phasic sigmoid colonic motility in healthy man: a double-blind crossover trial" BR. J. CLIN. PHARMACOL. (2000), 49(5), 429-436, XP001058300 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7470690B2 (en) 2002-07-10 2008-12-30 Dynogen Pharmaceuticals, Inc. 4-(2-Fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D)pyrimidine in the treatment of functional bowel disorder
WO2005072730A1 (fr) * 2004-01-30 2005-08-11 Astellas Pharma Inc. Agent therapeutique pour le syndrome de l’intestin irritable de type diarrhoe
WO2005073220A1 (fr) * 2004-01-30 2005-08-11 Yamanouchi Pharmaceutical Co., Ltd. Remede contre le syndrome du colon irritable avec diarrhee
JP2006008707A (ja) * 2005-09-21 2006-01-12 Astellas Pharma Inc 下痢型過敏性腸症候群治療剤

Also Published As

Publication number Publication date
HUP0301479A2 (hu) 2003-09-29
CZ2003158A3 (cs) 2003-08-13
MXPA02012917A (es) 2003-05-14
AR028970A1 (es) 2003-05-28
JP2004504343A (ja) 2004-02-12
PL363517A1 (en) 2004-11-29
SK1272003A3 (en) 2003-07-01
EP1307195A2 (fr) 2003-05-07
BR0112690A (pt) 2003-06-24
IL153972A0 (en) 2003-07-31
CN1444479A (zh) 2003-09-24
AU2001276409A1 (en) 2002-02-05
RU2003104798A (ru) 2004-06-27
NO20030373L (no) 2003-01-24
CA2417677A1 (fr) 2003-01-27
WO2002007713A3 (fr) 2002-11-14
NO20030373D0 (no) 2003-01-24

Similar Documents

Publication Publication Date Title
DE60103556T3 (de) Zusammensetzungen zur behandlung von fettleibigkeit, welche antagonisten der cb1-rezeptoren und sibutramine enthalten
DE60022021T2 (de) Zubereitungen enthaltend Apomorphin und Sildenafil und ihre Verwendung zur Behandlung von erektiler Dysfunktion
DE60218193T2 (de) Verwendung von 2-oxo-1-pyrrolidin-derivaten zur herstellung eines arzneimittels zur behandlung von dyskinesia
DE2523998A1 (de) Pharmazeutische zubereitung fuer die behandlung der schizophrenie
EP0752246A2 (fr) Agonistes des récepteurs kappa aux opioides pour des maladies inflammatoires de l'intestin
DE2823174A1 (de) Arzneimittel fuer die prophylaktische behandlung postoperativer tiefer venenthrombose
US6566369B2 (en) Medicament containing cilansetron for the treatment of non-obstipative male irritable bowel syndrome patients
DE60030654T2 (de) Verwendung von Lasofoxifen
DE3415394A1 (de) Medikament gegen ovarialinsuffizienz
DE60219940T2 (de) Verwendung von irbesartan zur vorbeugung oder behandlung pulmonaler hypertonie
WO2002007713A2 (fr) Medicament contenant du cilansetron pour traiter des patients masculins atteints du syndrome du colon irritable mais ne souffrant pas de constipation opiniatre
DE60204694T2 (de) Kombinationstherapie zur behandlung von herzinsuffizienz
DE602004005734T2 (de) Pharmazeutische zusammensetzung mit kontrollierter freisetzung und verfahren zu ihrer herstellung
DE69907387T2 (de) Verwendung von Hydantoin-Derivaten zur Herstellung eines Medikaments zur Behandlung von refraktärer Vasculitis.
DE60125062T2 (de) Quetiapin zur Behandlung der Dyskinesie in nicht-psychotischen Patienten
TWI289060B (en) Pharmaceutical composition for improving the recovery of post-stroke patients
WO2002080905A1 (fr) Agonistes opiaces de type kappa pour le traitement d'affections de la vessie
EP1001756A1 (fr) Compositions a effet synergique pour lutter selectivement contre les tissus tumoraux
DE60112750T2 (de) Pharmazeutische zusammensetzung enthaltend famotidine für die behandlung von depressionen
EP2120918B1 (fr) Composition pharmaceutique pour le traitement de l'incontinence
DE10123447A1 (de) Cilansetron enthaltende Arzneimittel zur Behandlung nicht-obstipativer männlicher IBS-Patienten
DE2823267C2 (fr)
DE2823268A1 (de) Blutdrucksenkendes mittel
DE3317280C2 (fr)
DE2532180C2 (de) Verwendung von Etozolin bei der Bekämpfung der Hypertonie

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: PA/a/2002/012917

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1020037000038

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 153972

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 200300445

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: PV2003-158

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 01813307X

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2417677

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2001954044

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1272003

Country of ref document: SK

WWE Wipo information: entry into national phase

Ref document number: 523959

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2001276409

Country of ref document: AU

Ref document number: 198/MUMNP/2003

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2003104798

Country of ref document: RU

Kind code of ref document: A

Ref country code: RU

Ref document number: RU A

WWP Wipo information: published in national office

Ref document number: 1020037000038

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: 2001954044

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: PV2003-158

Country of ref document: CZ

WWR Wipo information: refused in national office

Ref document number: PV2003-158

Country of ref document: CZ

WWW Wipo information: withdrawn in national office

Ref document number: 2001954044

Country of ref document: EP